CRISPR-engineered T cells in patients with refractory cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · see citing works

Multiplex Genome Engineering Using CRISPR/Cas Systems

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Cancer immunoediting: from immunosurveillance to tumor escape

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works

GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · see citing works

Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements

Kosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Gene Editing of <i>CCR5</i> in Autologous CD4 T Cells of Persons Infected with HIV

Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357 · see citing works

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102 · see citing works

Identification of preexisting adaptive immunity to Cas9 proteins in humans

Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093 · see citing works

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,075 · see citing works

Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition

Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942 · see citing works

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902 · see citing works

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 857 · see citing works

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807 · see citing works

A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells

Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782 · see citing works

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757 · see citing works

Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease.

Rouet, P., Smih, F., & Jasin, M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8096 · Cited by 739 · see citing works

Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer

Vilenchik, M. M., & Knudson, A. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135498100 · Cited by 717 · see citing works

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system

Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640 · see citing works

Lifespan of human lymphocyte subsets defined by CD45 isoforms

Michie, C. A., McLean, A. R., Alcock, C. J., & Beverley, P. C. L. (1992) · Nature · doi:10.1038/360264a0 · Cited by 635 · see citing works

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605 · see citing works

Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9

Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475 · see citing works

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells

Odorizzi, P. M., Pauken, K. E., Paley, M., Sharpe, A. H., & Wherry, E. J. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20142237 · Cited by 464 · see citing works

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia

Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454 · see citing works

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448 · see citing works

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A., Pouw, N. M. C., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 447 · see citing works

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · see citing works

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

D’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 432 · see citing works

High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population

Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schmueck-Henneresse, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0204-6 · Cited by 399 · see citing works

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2016) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 396 · see citing works

A versatile system for rapid multiplex genome-edited CAR T cell generation

Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 395 · see citing works

Introduction of Double-Strand Breaks into the Genome of Mouse Cells by Expression of a Rare-Cutting Endonuclease

Rouet, P., Smih, F., & Jasin, M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8096-8106.1994 · Cited by 363 · see citing works

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 310 · see citing works

In vivo estimates of division and death rates of human T lymphocytes.

Mclean, A. R., & Michie, C. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3707 · Cited by 270 · see citing works

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

Wartewig, T., Kurgyis, Z., Keppler, S. J., Pechloff, K., Hameister, E., Öllinger, R., Maresch, R., Buch, T., Steiger, K., Winter, C., et al. (2017) · Nature · doi:10.1038/nature24649 · Cited by 253 · see citing works

Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population

Simhadri, V. L., McGill, J., McMahon, S., Wang, J., Jiang, H., & Sauna, Z. E. (2018) · Molecular Therapy - Methods &amp; Clinical Development · doi:10.1016/j.omtm.2018.06.006 · Cited by 241 · see citing works

A New Class of Medicines through DNA Editing

Porteus, M. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800729 · Cited by 229 · see citing works

High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines

Zhao, Y., Bennett, A., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 221 · see citing works

Multifunctional CRISPR-Cas9 with Engineered Immunosilenced Human T Cell Epitopes

Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. R., Kiani, S., & Anderson, K. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09693-x · Cited by 204 · see citing works

Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines

Zhao, Y., Zheng, Z., Robbins, P. F., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4415 · Cited by 191 · see citing works

Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function

Schober, K., Müller, T. R., Gökmen, F., Grassmann, S., Effenberger, M., Poltorak, M., Stemberger, C., Schumann, K., Roth, T. L., Marson, A., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0409-0 · Cited by 178 · see citing works

Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State

Schietinger, A., Delrow, J. J., Basom, R., Blattman, J. N., & Greenberg, P. D. (2012) · Science · doi:10.1126/science.1214277 · Cited by 172 · see citing works

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

Bak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122 · see citing works

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

Moon, E. K., Ranganathan, R., Eruslanov, E. B., Kim, S., Newick, K., O’Brien, S., Lo, A., Liu, X., Zhao, Y., & Albelda, S. Μ. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1070 · Cited by 120 · see citing works

CRISPR–Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV–host factor interactions

Hultquist, J. F., Hiatt, J. B., Schumann, K., McGregor, M., Roth, T. L., Haas, P., Doudna, J. A., Marson, A., & Krogan, N. J. (2018) · Nature Protocols · doi:10.1038/s41596-018-0069-7 · Cited by 118 · see citing works

A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Nowicki, T. S., Berent-Maoz, B., Cheung-Lau, G. C., Huang, R., Wang, X., Tsoi, J., Kaplan‐Lefko, P. J., Cabrera, P. V., Tran, J., Pang, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3496 · Cited by 104 · see citing works

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade

Serganova, I. S., Moroz, E., Cohen, I., Moroz, M. A., Mane, M. M., Zurita, J., Shenker, L., Ponomarev, V., & Blasberg, R. G. (2016) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.11.005 · Cited by 93 · see citing works

Leukemia- and lymphoma-associated genetic aberrations in healthy individuals

Bäsecke, J., Griesinger, F., Trümper, L. H. P., et al. (2002) · Annals of Hematology · doi:10.1007/s00277-002-0427-x · Cited by 83 · see citing works

iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity

Nobles, C. L., Reddy, S. G., Salas-McKee, J., Liu, X., June, C. H., Melenhorst, J. J., Suhoski, M. M., Zhao, Y., & Bushman, F. D. (2019) · Genome biology · doi:10.1186/s13059-019-1625-3 · Cited by 82 · see citing works

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors

Menger, L., Śledzińska, A., Bergerhoff, K. F., Vargas, F. A., Smith, J. N. P., Poirot, L., Pulè, M. A., Herrero, J., Peggs, K. S., & Quezada, S. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3352 · Cited by 79 · see citing works

Incidence of bcr-abl fusion transcripts in healthy individuals

Ismail, S. I., Naffa, R. G., Yousef, A., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1951 · Cited by 56 · see citing works

Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution

Bownds, S., Tong-On, P., Rosenberg, S. A., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200101000-00001 · Cited by 39 · see citing works

Persistence of space radiation induced cytogenetic damage in the blood lymphocytes of astronauts

George, K. A., Chappell, L. J., & Cucinotta, F. A. (2010) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2010.02.007 · Cited by 37 · see citing works

Translocations in Normal B Cells and Cancers

Chiarle, R. (2013) · Advances in immunology · doi:10.1016/b978-0-12-410524-9.00002-5 · Cited by 10 · see citing works

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687 · see citing works

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852 · see citing works

Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins

Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668 · see citing works

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674 · see citing works

Past, present, and future of CRISPR genome editing technologies

Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609 · see citing works

mRNA-based cancer therapeutics

Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500 · see citing works

Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing

Mengstie, M. A., & Wondimu, B. Z. (2021) · Biologics: Targets and Therapy · doi:10.2147/btt.s326422 · Cited by 478 · see citing works

Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence

Belk, J. A., Yao, W., Ly, N., Freitas, K. A., Chen, Y.-T., Shi, Q., Valencia, A. M., Shifrut, E., Kale, N., Yost, K. E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.001 · Cited by 382 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges

Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259 · see citing works

Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy

Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251 · see citing works

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186 · see citing works

Designing and executing prime editing experiments in mammalian cells

Doman, J. L., Sousa, A. A., Randolph, P. B., Chen, P. J., & Liu, D. R. (2022) · Nature Protocols · doi:10.1038/s41596-022-00724-4 · Cited by 172 · see citing works

Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity

Kiesgen, S., Messinger, J. C., Chintala, N. K., Tano, Z., & Adusumilli, P. S. (2021) · Nature Protocols · doi:10.1038/s41596-020-00467-0 · Cited by 138 · see citing works

CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells

Kluesner, M. G., Lahr, W. S., Lonetree, C.-L., Smeester, B. A., Qiu, X., Slipek, N. J., Claudio Vázquez, P. N., Pitzen, S. P., Pomeroy, E. J., Vignes, M. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22009-2 · Cited by 121 · see citing works

High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA

Oh, S. A., Senger, K., Madireddi, S., Akhmetzyanova, I., Ishizuka, I. E., Tarighat, S., Lo, J. H., Shaw, D., Haley, B., & Rutz, S. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211530 · Cited by 88 · see citing works

Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells

Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Pruß, A., Schmueck-Henneresse, M., Volk, H.-D., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02928-7 · Cited by 65 · see citing works

Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?

Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63 · see citing works

Breaking Bottlenecks for the TCR Therapy of Cancer

Gaissmaier, L., Elshiaty, M., & Christopoulos, P. (2020) · Cells · doi:10.3390/cells9092095 · Cited by 52 · see citing works

Learning from the nexus of autoimmunity and cancer

Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33 · see citing works

Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases

Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32 · see citing works

Extru-seq: A method for predicting genome-wide Cas9 off-target sites with advantages of both cell-based and in vitro approaches

Kwon, J., Kim, M., Hwang, W., Jo, A., Hwang, G.-H., Jung, M., Kim, U. G., Cui, G., Kim, H., Eom, J.-H., et al. (2023) · Genome biology · doi:10.1186/s13059-022-02842-4 · Cited by 24 · see citing works

Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells

Hunt, J., Samson, C., du Rand, A., & Sheppard, H. M. (2023) · Human Genetics · doi:10.1007/s00439-023-02561-1 · Cited by 125 · see citing works

Elevated expression of exogenous RAD51 enhances the CRISPR/Cas9-mediated genome editing efficiency

Park, S. J., Yoon, S., Choi, E.-H., Hyeon, H., Lee, K., & Kim, K. P. (2023) · BMB Reports · doi:10.5483/bmbrep.2022-0149 · Cited by 12 · see citing works

Temperature effect on CRISPR-Cas9 mediated genome editing

Xiang, G., Zhang, X., An, C., Cheng, C., & Wang, H. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.03.004 · Cited by 95 · see citing works

CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases

Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 18 · see citing works

Therapeutic applications of CRISPR RNA-guided genome editing

Koo, T., & Kim, J. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw032 · Cited by 24 · see citing works